Robert S Wilson1, Ana W Capuano2, Patricia A Boyle2, George M Hoganson2, Loren P Hizel2, Raj C Shah2, Sukriti Nag2, Julie A Schneider2, Steven E Arnold2, David A Bennett2. 1. From the Rush Alzheimer's Disease Center (R.S.W., A.W.C., P.A.B., G.M.H., L.P.H., R.C.S., S.N., J.A.S., D.A.B.) and Departments of Behavioral Sciences (R.S.W., P.A.B.), Neurological Sciences (R.S.W., A.W.C., J.A.S., D.A.B.), Pathology (S.N., J.A.S.), and Family Medicine (R.C.S.), Rush University Medical Center, Chicago, IL; and Departments of Psychiatry and Neurology (S.E.A.), University of Pennsylvania, Philadelphia. rwilson@rush.edu. 2. From the Rush Alzheimer's Disease Center (R.S.W., A.W.C., P.A.B., G.M.H., L.P.H., R.C.S., S.N., J.A.S., D.A.B.) and Departments of Behavioral Sciences (R.S.W., P.A.B.), Neurological Sciences (R.S.W., A.W.C., J.A.S., D.A.B.), Pathology (S.N., J.A.S.), and Family Medicine (R.C.S.), Rush University Medical Center, Chicago, IL; and Departments of Psychiatry and Neurology (S.E.A.), University of Pennsylvania, Philadelphia.
Abstract
OBJECTIVE: To clarify the relationship between depressive symptoms and the clinical and neuropathologic manifestations of dementia. METHODS: In a clinical-pathologic cohort study, 1,764 older persons without cognitive impairment at enrollment completed annual clinical evaluations for a mean of 7.8 years. The evaluations included assessment of depressive symptoms (10-item Center for Epidemiological Studies Depression Scale) and cognitive function (battery of 17 performance tests). A total of 582 individuals died during follow-up and underwent a uniform neuropathologic examination to quantify β-amyloid plaques and tau tangle density in multiple brain regions and identify neocortical Lewy bodies, hippocampal sclerosis, and gross and microscopic cerebral infarcts. RESULTS: Level of depressive symptoms slightly increased during follow-up. Incident mild cognitive impairment (52.2%) was associated with higher level of depressive symptoms before the diagnosis but not with change in symptoms after the diagnosis; incident dementia (17.9%) was associated with higher symptom level before dementia onset and with more rapid decline in symptoms after dementia onset. None of the neuropathologic markers was related to level of depressive symptoms or change in symptoms over time. In a mixed-effects model adjusted for the neuropathologic markers, higher level of depressive symptoms averaged over evaluations was associated with more rapid global cognitive decline, accounting for 4.4% of the variability in decline not attributable to the neuropathologic markers. Depressive symptoms did not modify the association of the neuropathologic markers with cognitive decline. CONCLUSION: In old age, depressive symptoms have an association with cognitive decline that is independent of the neuropathologic hallmarks of dementia.
OBJECTIVE: To clarify the relationship between depressive symptoms and the clinical and neuropathologic manifestations of dementia. METHODS: In a clinical-pathologic cohort study, 1,764 older persons without cognitive impairment at enrollment completed annual clinical evaluations for a mean of 7.8 years. The evaluations included assessment of depressive symptoms (10-item Center for Epidemiological Studies Depression Scale) and cognitive function (battery of 17 performance tests). A total of 582 individuals died during follow-up and underwent a uniform neuropathologic examination to quantify β-amyloid plaques and tau tangle density in multiple brain regions and identify neocortical Lewy bodies, hippocampal sclerosis, and gross and microscopic cerebral infarcts. RESULTS: Level of depressive symptoms slightly increased during follow-up. Incident mild cognitive impairment (52.2%) was associated with higher level of depressive symptoms before the diagnosis but not with change in symptoms after the diagnosis; incident dementia (17.9%) was associated with higher symptom level before dementia onset and with more rapid decline in symptoms after dementia onset. None of the neuropathologic markers was related to level of depressive symptoms or change in symptoms over time. In a mixed-effects model adjusted for the neuropathologic markers, higher level of depressive symptoms averaged over evaluations was associated with more rapid global cognitive decline, accounting for 4.4% of the variability in decline not attributable to the neuropathologic markers. Depressive symptoms did not modify the association of the neuropathologic markers with cognitive decline. CONCLUSION: In old age, depressive symptoms have an association with cognitive decline that is independent of the neuropathologic hallmarks of dementia.
Authors: David A Bennett; Julie A Schneider; Aron S Buchman; Lisa L Barnes; Patricia A Boyle; Robert S Wilson Journal: Curr Alzheimer Res Date: 2012-07 Impact factor: 3.498
Authors: Robert S Wilson; Lei Yu; Julie A Schneider; Steven E Arnold; Aron S Buchman; David A Bennett Journal: Chem Senses Date: 2011-01-21 Impact factor: 3.160
Authors: Tessa N van den Kommer; Hannie C Comijs; Marja J Aartsen; Martijn Huisman; Dorly J H Deeg; Aartjan T F Beekman Journal: Am J Geriatr Psychiatry Date: 2013-02-06 Impact factor: 4.105
Authors: Deborah E Barnes; Kristine Yaffe; Amy L Byers; Mark McCormick; Catherine Schaefer; Rachel A Whitmer Journal: Arch Gen Psychiatry Date: 2012-05
Authors: Robert S Wilson; Sukriti Nag; Patricia A Boyle; Loren P Hizel; Lei Yu; Aron S Buchman; Raj C Shah; Julia A Schneider; Steven E Arnold; David A Bennett Journal: JAMA Psychiatry Date: 2013-12 Impact factor: 21.596
Authors: Claire E Sexton; Charlotte L Allan; Marisa Le Masurier; Lisa M McDermott; Ukwuori G Kalu; Lucie L Herrmann; Matthias Mäurer; Kevin M Bradley; Clare E Mackay; Klaus P Ebmeier Journal: Arch Gen Psychiatry Date: 2012-07
Authors: Robert S Wilson; Patricia A Boyle; Lei Yu; Lisa L Barnes; Joel Sytsma; Aron S Buchman; David A Bennett; Julie A Schneider Journal: Neurology Date: 2015-08-26 Impact factor: 9.910
Authors: Thomas S Wingo; Jingjing Yang; Wen Fan; Se Min Canon; Ekaterina Sergeevna Gerasimov; Adriana Lori; Benjamin Logsdon; Bing Yao; Nicholas T Seyfried; James J Lah; Allan I Levey; Patricia A Boyle; Julia A Schneider; Philip L De Jager; David A Bennett; Aliza P Wingo Journal: NPJ Genom Med Date: 2020-02-06 Impact factor: 8.617
Authors: Meghan Riddle; Guy G Potter; Douglas R McQuoid; David C Steffens; John L Beyer; Warren D Taylor Journal: Am J Geriatr Psychiatry Date: 2017-03-28 Impact factor: 4.105
Authors: Laura B Zahodne; Neika Sharifian; Jennifer J Manly; Jennifer A Sumner; Michael Crowe; Virginia G Wadley; Virginia J Howard; Audrey R Murchland; Willa D Brenowitz; Jennifer Weuve Journal: Psychol Aging Date: 2019-09-30
Authors: Lei Yu; Patricia A Boyle; Eisuke Segawa; Sue Leurgans; Julie A Schneider; Robert S Wilson; David A Bennett Journal: Neuropsychology Date: 2014-12-15 Impact factor: 3.295